Published in J Clin Microbiol on July 03, 2012
Epitopes of the highly immunogenic Trichomonas vaginalis α-actinin are serodiagnostic targets for both women and men. J Clin Microbiol (2013) 1.03
Comparative evaluation of blood and serum samples in rapid immunochromatographic tests for visceral leishmaniasis. J Clin Microbiol (2013) 0.81
Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet (1998) 3.55
Comparative evaluation of parasitology and serological tests in the diagnosis of visceral leishmaniasis in India: a phase III diagnostic accuracy study. Trop Med Int Health (2007) 1.77
Serological diagnosis of Indian visceral leishmaniasis: direct agglutination test versus rK39 strip test. Trans R Soc Trop Med Hyg (2005) 1.75
Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. Am J Trop Med Hyg (2009) 1.34
The epidemiology of Leishmania donovani infection in high transmission foci in India. Trop Med Int Health (2010) 1.30
Cloning, expression, and purification of a novel recombinant antigen from Leishmania donovani. Protein Expr Purif (2005) 1.19
Expression and characterization of a recombinant kinesin antigen from an old Indian strain (DD8) of Leishmania donovani and comparing it with a commercially available antigen from a newly isolated (KE16) strain of L. donovani. Infect Genet Evol (2008) 1.07
False-positive results of a rapid K39-based strip test and Chagas disease. Int J Infect Dis (2008) 0.94
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol (2007) 7.36
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis (2002) 7.17
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet (2011) 2.81
Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med (2007) 2.75
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis (2007) 2.74
Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med (2010) 2.68
Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis (2009) 2.56
Leishmaniasis: new approaches to disease control. BMJ (2003) 2.30
Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ (2010) 2.30
Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res (2011) 2.21
Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis (2011) 2.19
Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis (2006) 2.17
High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res (2010) 2.11
Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis (2005) 2.06
Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother (2012) 2.03
Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis (2012) 2.00
Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. Am J Trop Med Hyg (2005) 1.96
Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg (2010) 1.93
Novel and high volume use flame retardants in US couches reflective of the 2005 PentaBDE phase out. Environ Sci Technol (2012) 1.79
Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem (2004) 1.79
Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol (2006) 1.75
Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal. Am J Trop Med Hyg (2010) 1.74
Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl Trop Dis (2011) 1.67
Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis (2011) 1.64
Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence? Trop Med Int Health (2008) 1.63
Effect of village-wide use of long-lasting insecticidal nets on visceral Leishmaniasis vectors in India and Nepal: a cluster randomized trial. PLoS Negl Trop Dis (2010) 1.61
Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment. Trop Med Int Health (2008) 1.59
A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis (2012) 1.59
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat (2006) 1.58
Endocrine changes in male HIV patients. J Assoc Physicians India (2011) 1.56
Drug resistance in leishmaniasis. J Glob Infect Dis (2010) 1.52
Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol (2007) 1.50
Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent. Infect Genet Evol (2008) 1.49
Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol (2011) 1.48
Identification of genetic markers in sodium antimony gluconate (SAG) sensitive and resistant Indian clinical isolates of Leishmania donovani through amplified fragment length polymorphism (AFLP). Acta Trop (2009) 1.47
Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis (2003) 1.46
IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol (2011) 1.44
Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS Negl Trop Dis (2011) 1.42
Knowledge, attitude, and practices related to Kala-azar in a rural area of Bihar state, India. Am J Trop Med Hyg (2006) 1.40
A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics (2006) 1.36
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res (2005) 1.36
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis (2010) 1.35
Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop Med Int Health (2006) 1.35
Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. Am J Trop Med Hyg (2009) 1.34
Correlation between CD4 counts of HIV patients and enteric protozoan in different seasons - an experience of a tertiary care hospital in Varanasi (India). BMC Gastroenterol (2008) 1.34
Diarrhea, CD4 counts and enteric infections in a hospital - based cohort of HIV-infected patients around Varanasi, India. BMC Infect Dis (2006) 1.33
IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis (2011) 1.33
The epidemiology of Leishmania donovani infection in high transmission foci in India. Trop Med Int Health (2010) 1.30
Measurement of recent exposure to Phlebotomus argentipes, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. Am J Trop Med Hyg (2010) 1.30
Characterization of natural antimony resistance in Leishmania donovani isolates. Am J Trop Med Hyg (2007) 1.29
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis (2012) 1.27
Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother (2008) 1.26
Evaluation of leishmanin skin test in Indian visceral leishmaniasis. Am J Trop Med Hyg (2009) 1.22
Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin Vaccine Immunol (2012) 1.20
Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother (2011) 1.19
Case study for a vaccine against leishmaniasis. Vaccine (2013) 1.19
Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Ther Clin Risk Manag (2007) 1.17
A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg (2005) 1.17
Persistence of Leishmania donovani antibodies in past visceral leishmaniasis cases in India. Clin Vaccine Immunol (2010) 1.16
Latent infection with Leishmania donovani in highly endemic villages in Bihar, India. PLoS Negl Trop Dis (2013) 1.16
Antimony toxicity. Int J Environ Res Public Health (2010) 1.15
Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection. Antimicrob Agents Chemother (2007) 1.15
Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat Genet (2013) 1.15
Diagnosis of Indian visceral leishmaniasis by nucleic acid detection using PCR. PLoS One (2011) 1.14
Evaluation of blood agar microtiter plates for culturing leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis. J Clin Microbiol (2010) 1.13
A multiattribute utility evaluation of different methods for the detection of enteric protozoa causing diarrhea in AIDS patients. BMC Microbiol (2010) 1.13
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine (2011) 1.13
Population preference of net texture prior to bed net trial in Kala-Azar-endemic areas. PLoS Negl Trop Dis (2007) 1.13
Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob Agents Chemother (2005) 1.12
Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. J Antimicrob Chemother (2011) 1.11
Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for Leishmania donovani, a proof of concept study. PLoS Negl Trop Dis (2011) 1.11
Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. Int J Parasitol (2011) 1.10
Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India. Infect Genet Evol (2010) 1.09
Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. Trop Med Int Health (2012) 1.09
Serological markers of sand fly exposure to evaluate insecticidal nets against visceral leishmaniasis in India and Nepal: a cluster-randomized trial. PLoS Negl Trop Dis (2011) 1.08
Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology. PLoS One (2006) 1.08
Asymptomatic Leishmania infection: a new challenge for Leishmania control. Clin Infect Dis (2014) 1.07
Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. Proc Natl Acad Sci U S A (2013) 1.07
CD8 T cell exhaustion in human visceral leishmaniasis. J Infect Dis (2013) 1.06
Visceral leishmaniasis in Muzaffarpur district, Bihar, India from 1990 to 2008. PLoS One (2011) 1.06
Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Mol Biochem Parasitol (2010) 1.05
Determinants of survival in adult HIV patients on antiretroviral therapy in Eastern Uttar Pradesh: a prospective study. Indian J Med Res (2014) 1.04
Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. J Infect Dis (2008) 1.03
Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani. J Antimicrob Chemother (2010) 1.03
Residual activity and integrity of PermaNet® 2.0 after 24 months of household use in a community randomised trial of long lasting insecticidal nets against visceral leishmaniasis in India and Nepal. Trans R Soc Trop Med Hyg (2011) 1.03
Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs (2008) 1.03
An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother (2014) 1.03
Functionality of drug efflux pumps in antimonial resistant Leishmania donovani field isolates. Indian J Biochem Biophys (2009) 1.02
Comparative evaluation of freeze-dried and liquid antigens in the direct agglutination test for serodiagnosis of visceral leishmaniasis (ITMA-DAT/VL). Trop Med Int Health (2006) 1.02
Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Trop Med Int Health (2009) 1.01
Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani. Parasitol Res (2012) 1.00
Novel mechanism of drug resistance in kala azar field isolates. J Infect Dis (2003) 0.99
Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. Clin Infect Dis (2009) 0.99
Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol. PLoS Negl Trop Dis (2012) 0.98
Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex. Infect Genet Evol (2011) 0.98